CVS Health Corp vs Garmin Ltd. — how do they compare? CVS Health Corp trades at $86.85 (market cap $112.49B), while Garmin Ltd. trades at $271.28 (market cap $53.26B). The key difference: CVS Health Corp is far larger — about 2.1× Garmin Ltd.'s market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Garmin Ltd. for 83 Days on average.
| CVS | GRMN | |
|---|---|---|
Market Cap | $112.49B | $53.26B |
Volume | 8,467,392 | 529,054 |
Sector | Health | Technology |
52-Week High | $110.60 | $313.16 |
52-Week Low | $70.08 | $187.10 |
Typical Hold Time | 83 Days | 83 Days |
Enterprise Value | $174.83B | $50.77B |
Dividend Yield | 3.02% | 1.52% |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Garmin (GRMN) trades at $268.44, down 3.86% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.81 beating estimates of $2.30. Revenue growth remains robust, rising from $4.9B in 2022 to $7.25B in 2025, with net income margins above 20%. Recent positive developments include multiple product awards and new feature rollouts across marine, automotive, and fitness segments.
Garmin presents a compelling investment case with strong profitability and consistent execution, though near-term technical pressure and cautious analyst sentiment (71% hold rating) suggest potential volatility. The consensus price target of $320.25 implies 19% upside, but investors should monitor competitive pressures in the wearable tech space and macroeconomic factors affecting consumer discretionary spending.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →